CMRX vs. BHVN, MTSR, ACAD, MOR, RXRX, XENE, AMRX, CPRX, HCM, and BHC
Should you be buying Chimerix stock or one of its competitors? The main competitors of Chimerix include Biohaven (BHVN), Metsera (MTSR), ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), Recursion Pharmaceuticals (RXRX), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical products" industry.
Chimerix vs.
Biohaven (NYSE:BHVN) and Chimerix (NASDAQ:CMRX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership.
Biohaven has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Chimerix has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500.
Biohaven presently has a consensus price target of $63.15, suggesting a potential upside of 111.93%. Chimerix has a consensus price target of $8.53, suggesting a potential upside of 0.27%. Given Biohaven's stronger consensus rating and higher possible upside, analysts plainly believe Biohaven is more favorable than Chimerix.
88.8% of Biohaven shares are owned by institutional investors. Comparatively, 45.4% of Chimerix shares are owned by institutional investors. 16.0% of Biohaven shares are owned by insiders. Comparatively, 13.1% of Chimerix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Chimerix's return on equity of -50.78% beat Biohaven's return on equity.
Biohaven received 10 more outperform votes than Chimerix when rated by MarketBeat users. Likewise, 67.44% of users gave Biohaven an outperform vote while only 63.36% of users gave Chimerix an outperform vote.
In the previous week, Chimerix had 4 more articles in the media than Biohaven. MarketBeat recorded 8 mentions for Chimerix and 4 mentions for Biohaven. Chimerix's average media sentiment score of 0.94 beat Biohaven's score of 0.69 indicating that Chimerix is being referred to more favorably in the news media.
Chimerix has higher revenue and earnings than Biohaven. Chimerix is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
Summary
Biohaven beats Chimerix on 10 of the 17 factors compared between the two stocks.
Get Chimerix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chimerix Competitors List
Related Companies and Tools
This page (NASDAQ:CMRX) was last updated on 3/26/2025 by MarketBeat.com Staff
